All In Biotech

Drug Trial Radar · NCT06016517

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Tufts Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are: * What are the effects of different treatments on RA symptoms and condition for each individual patient * What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).

Conditions

  • Arthritis, Rheumatoid

Interventions

  • EtanerceptDrug

    50 mg subcutaneously weekly

  • AdalimumabDrug

    40 mg subcutaneously every 2 weeks

  • UpadacitinibDrug

    15 mg orally once daily with subcutaneous placebo injection every 2 weeks

  • TocilizumabDrug

    162 mg administered SQ every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Disease Activity Score (DAS) 28Time frame: Baseline and week 12 of each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.